search
Back to results

DOLPHIN-VIVO: Diagnosis Of LymPHoma IN Vivo (In Vivo Phase) (DOLPHIN-VIVO)

Primary Purpose

Lymphoma, Head and Neck Cancer

Status
Not yet recruiting
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
spectroscopic measurement
FNA biopsy
histopathology and cytology
Sponsored by
University of Exeter
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional device feasibility trial for Lymphoma focused on measuring Raman, Lymphoma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients undergoing biopsy or excision of more than one lymph node as part of their routine clinical care within Gloucestershire Hospitals NHS Foundation Trust.
  • Patients undergoing lymphadenectomy as part of routine treatment

Exclusion Criteria:

  • Patients requiring biopsy of only one lymph node
  • Patients unable to consent to the study due to communication difficulties
  • Patients unable to consent to the study due to lack of capacity

Sites / Locations

  • Gloucestershire Hospitals NHS Foundation Trust

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

non-hodgkin lymphoma

hodgkin lymphoma

squamous cell carcinoma

reactive

other

Arm Description

patients diagnosed with non-hodgkin lymphoma

patients diagnosed with hodgkin lymphoma

patients diagnosed with squamous cell carcinoma

patients diagnosed with a reactive (non-cancerous) lymph node

none of the above. Other cancer and non-cancer conditions

Outcomes

Primary Outcome Measures

Safety of in vivo measurement of lymph nodes using Raman spectroscopy to acquire diagnostic quality spectra
Testing of the device for clinical application during surgery to demonstrate its use is safe and that is able to acquire diagnostic-quality spectra in less than 5 seconds from lymph nodes.

Secondary Outcome Measures

Safe in vivo measurement of lymph nodes using Raman spectroscopy to acquire diagnostic quality spectra
Computer model using multivariate analysis able to discriminate between diseased and non-diseased tissue. The target specificity and sensitivity are low due to small study group sizes.

Full Information

First Posted
May 20, 2021
Last Updated
May 26, 2022
Sponsor
University of Exeter
Collaborators
Gloucestershire Hospitals NHS Foundation Trust, University of Bristol
search

1. Study Identification

Unique Protocol Identification Number
NCT05010369
Brief Title
DOLPHIN-VIVO: Diagnosis Of LymPHoma IN Vivo (In Vivo Phase)
Acronym
DOLPHIN-VIVO
Official Title
Diagnosis Of Lymphoma In Vivo Using Vibrational Spectroscopy (In Vivo Phase)
Study Type
Interventional

2. Study Status

Record Verification Date
May 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
January 2023 (Anticipated)
Primary Completion Date
March 2023 (Anticipated)
Study Completion Date
March 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Exeter
Collaborators
Gloucestershire Hospitals NHS Foundation Trust, University of Bristol

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Lymphoma diagnosis often involves removal and biopsy of one or more lymph nodes. Many (around half) of these diagnostic procedures show that no cancer is present, hence unnecessary removal results in numerous side effects and complications. The procedure is also highly invasive. The investigators have already shown that it is possible to tell the difference between healthy and diseased tissue in the laboratory by looking at the light emitted by tissue when a low power laser is shone on to it. The investigators intend to use this technique, known as "Raman Spectroscopy" (RS) to tell if tissue in the node is cancerous or healthy. By combining RS with a fine needle, the technique can target tissues below the skin with minimal invasion. Our needle will provide the clinician with instant diagnosis without the delay and cost of a laboratory analysis by pathologists. The investigators have designed a probe that slides through a fine needle, guided by ultrasound, to the lymph node. The space between the two needles provides space for cell aspirate. The investigators propose to measure spectra from excess lymph node biopsy samples taken during standard routine diagnostic biopsy. The investigators are also interested to see if they can successfully extract a fine needle aspiration (FNA) biopsy sample using the device, as well as record a RS measurement. If successful this would ease clinical adoption as the study could run in parallel with existing standard routine clinical practice, using just one device. This study will evaluate the new device on half a lymph node that will be excised and snap-frozen during a routine surgical biopsy, to gather data for submission of approvals for an in-vivo study to follow.
Detailed Description
Surplus lymph node tissue collected from patients undergoing routine surgical treatment for head & neck disease will be investigated using vibrational spectroscopy. The project will develop a combined FNA/Raman spectroscopy needle probe. This study will evaluate this device on excised lymph node tissue to gather data for submission of approvals for an in-vivo study to follow. Raman & FTIR (fourier transform infrared) spectra will be correlated with routine histopathology results using multivariate analysis methods. Cytology samples taken using the device will be compared with histopathology results. Aims To demonstrate that the FNA/Raman spectroscopy probe device, developed as part of this project, can: Safely perform measurement of Raman spectra on excised lymph node tissue Safely perform FNA (fine needle aspiration) biopsies on excised lymph node tissue To evaluate the performance of a Raman needle probe to detect lymphoma & malignancy in excised head & neck lymph nodes and differentiate from benign nodes. To develop the investigators understanding of vibrational spectroscopy signal characteristics in head & neck lymph nodes (through Raman & FTIR mapping measurements of tissue sections). Objectives To test a new combined FNA and spectroscopic device on ex vivo tissue in preparation for an in vivo study. Outcome Primary Outcome Measures The FNA/Raman spectroscopy probe device can be used safely on excised lymph nodes to measure tissue spectra and collect FNA biopsies. Diagnostic performance of vibrational spectroscopy for differentiation of lymphoma & malignant nodes from benign nodes. Secondary Outcome Measures Evaluation of the performance of a Raman needle probe to detect lymphoma & malignancy in excised head & neck lymph nodes and differentiate from benign nodes. To develop the investigators understanding of vibrational spectroscopy signal characteristics in head & neck lymph nodes (through Raman & FTIR mapping measurements of tissue sections). Evaluation of the performance of a Raman needle probe to measure head & neck lymph nodes (ergonomic design, ease of use etc.).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lymphoma, Head and Neck Cancer
Keywords
Raman, Lymphoma

7. Study Design

Primary Purpose
Device Feasibility
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
45 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
non-hodgkin lymphoma
Arm Type
Experimental
Arm Description
patients diagnosed with non-hodgkin lymphoma
Arm Title
hodgkin lymphoma
Arm Type
Experimental
Arm Description
patients diagnosed with hodgkin lymphoma
Arm Title
squamous cell carcinoma
Arm Type
Experimental
Arm Description
patients diagnosed with squamous cell carcinoma
Arm Title
reactive
Arm Type
Experimental
Arm Description
patients diagnosed with a reactive (non-cancerous) lymph node
Arm Title
other
Arm Type
Experimental
Arm Description
none of the above. Other cancer and non-cancer conditions
Intervention Type
Diagnostic Test
Intervention Name(s)
spectroscopic measurement
Other Intervention Name(s)
raman, infra red
Intervention Description
measurement of the tissue with spectroscopy
Intervention Type
Diagnostic Test
Intervention Name(s)
FNA biopsy
Other Intervention Name(s)
fine needle aspiration biopsy
Intervention Description
a fine needle aspiration (FNA) biopsy will be taken
Intervention Type
Diagnostic Test
Intervention Name(s)
histopathology and cytology
Intervention Description
Histopathology and cytology will be performed on the samples
Primary Outcome Measure Information:
Title
Safety of in vivo measurement of lymph nodes using Raman spectroscopy to acquire diagnostic quality spectra
Description
Testing of the device for clinical application during surgery to demonstrate its use is safe and that is able to acquire diagnostic-quality spectra in less than 5 seconds from lymph nodes.
Time Frame
3 years
Secondary Outcome Measure Information:
Title
Safe in vivo measurement of lymph nodes using Raman spectroscopy to acquire diagnostic quality spectra
Description
Computer model using multivariate analysis able to discriminate between diseased and non-diseased tissue. The target specificity and sensitivity are low due to small study group sizes.
Time Frame
3 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients undergoing biopsy or excision of more than one lymph node as part of their routine clinical care within Gloucestershire Hospitals NHS Foundation Trust. Patients undergoing lymphadenectomy as part of routine treatment Exclusion Criteria: Patients requiring biopsy of only one lymph node Patients unable to consent to the study due to communication difficulties Patients unable to consent to the study due to lack of capacity
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Pam Baxter
Phone
01392 723588
Email
P.R.Baxter2@exeter.ac.uk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nick Stone
Organizational Affiliation
University of Exeter
Official's Role
Principal Investigator
Facility Information:
Facility Name
Gloucestershire Hospitals NHS Foundation Trust
City
Gloucester
State/Province
Gloucestershire
ZIP/Postal Code
GL1 3NN
Country
United Kingdom
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Julia Hall
Phone
03004225466
Email
julia.hall9@nhs.net
First Name & Middle Initial & Last Name & Degree
Charlie Hall

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
Unique study number and MRN (medical records number) (hospital number)

Learn more about this trial

DOLPHIN-VIVO: Diagnosis Of LymPHoma IN Vivo (In Vivo Phase)

We'll reach out to this number within 24 hrs